MX9703889A - Peptido rantes y fragmentos y composiciones que lo contienen, para el tratamiento de la inflamacion. - Google Patents

Peptido rantes y fragmentos y composiciones que lo contienen, para el tratamiento de la inflamacion.

Info

Publication number
MX9703889A
MX9703889A MX9703889A MX9703889A MX9703889A MX 9703889 A MX9703889 A MX 9703889A MX 9703889 A MX9703889 A MX 9703889A MX 9703889 A MX9703889 A MX 9703889A MX 9703889 A MX9703889 A MX 9703889A
Authority
MX
Mexico
Prior art keywords
inflammation
rantes
fragments
compositions
treatment
Prior art date
Application number
MX9703889A
Other languages
English (en)
Other versions
MXPA97003889A (es
Inventor
Timothy Nigel Carl Wells
Amanda Elizabeth Inn Proudfoot
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9424835.8A external-priority patent/GB9424835D0/en
Priority claimed from GBGB9512319.6A external-priority patent/GB9512319D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MXPA97003889A publication Critical patent/MXPA97003889A/es
Publication of MX9703889A publication Critical patent/MX9703889A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las modificaciones a RANTES pueden dar como resultado el polipéptido modificado que actua como un antagonista de RANTES o de MIP-1alfa. Tales antagonistas pueden ser utilizados en terapia para reducir la inflamacion. Estos puede también serutiles en el estudio de las propiedades de RANTES o de MIP-1alfa.
MX9703889A 1994-12-08 1995-12-07 Peptido rantes y fragmentos y composiciones que lo contienen, para el tratamiento de la inflamacion. MX9703889A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9424835.8A GB9424835D0 (en) 1994-12-08 1994-12-08 Substances and their uses
GB9424835.8 1994-12-08
GBGB9512319.6A GB9512319D0 (en) 1995-06-16 1995-06-16 Substances and their uses
GB9512319.6 1995-06-16
PCT/GB1995/002861 WO1996017935A2 (en) 1994-12-08 1995-12-07 Rantes peptide and fragments and compositions comprising it for treatment of inflammation

Publications (2)

Publication Number Publication Date
MXPA97003889A MXPA97003889A (es) 1997-08-01
MX9703889A true MX9703889A (es) 1997-08-30

Family

ID=26306133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9703889A MX9703889A (es) 1994-12-08 1995-12-07 Peptido rantes y fragmentos y composiciones que lo contienen, para el tratamiento de la inflamacion.

Country Status (15)

Country Link
US (2) US6159711A (es)
EP (1) EP0796330A1 (es)
JP (1) JPH10510151A (es)
CN (1) CN1087346C (es)
AU (1) AU688641B2 (es)
BR (1) BR9509890A (es)
CA (1) CA2207036A1 (es)
CZ (1) CZ290850B6 (es)
FI (1) FI972433A0 (es)
HU (1) HU221089B1 (es)
MX (1) MX9703889A (es)
NO (1) NO972620L (es)
NZ (1) NZ296570A (es)
PL (1) PL182786B1 (es)
WO (1) WO1996017935A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0796330A1 (en) * 1994-12-08 1997-09-24 Glaxo Group Limited Rantes peptide and fragments and compositions comprising it for treatment of inflammation
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
EP0972043A1 (en) * 1996-09-25 2000-01-19 British Biotech Pharmaceuticals Limited Human rantes mutants incapable of aggregate formation
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
IT1291353B1 (it) * 1997-05-12 1999-01-07 San Raffaele Centro Fond Peptidi con attivita' antivirale
US6168784B1 (en) 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
EP0906954A1 (en) 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
AU2415599A (en) * 1997-12-23 1999-07-19 Fondazione Centro San Raffaele Del Monte Tabor Rantes mutants and therapeutic applications thereof
US6121023A (en) 1998-01-22 2000-09-19 Akzo Nobel N.V. Isothermal transcription based assay for the detection and quantification of the chemokine rantes
EP1000626A1 (en) * 1998-09-18 2000-05-17 Applied Research Systems ARS Holding N.V. Chemokine receptor antagonist and cyclosporin in combined therapy
IT1303736B1 (it) * 1998-11-11 2001-02-23 San Raffaele Centro Fond Peptidi derivati da rantes con attivita' anti-hiv.
WO2000056879A1 (en) * 1999-03-22 2000-09-28 Universität Zürich TRANSFORMING GROWTH FACTOR (TFG) β SUPERFAMILY ANTAGONISTS
HUP0303854A2 (hu) 2000-09-08 2004-03-01 Gryhon Therapeutics, Inc. Szintetikus erythropoiesis-stimuláló proteinek
US7998681B2 (en) 2000-10-06 2011-08-16 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Diagnosis and therapy of antibody-mediated inflammatory auto-immune disorders
US8153121B2 (en) * 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
EP1506400A2 (en) * 2001-10-30 2005-02-16 President And Fellows Of Harvard College Pathway of rantes-mediated chemokine synthesis in astrocytes and methods of use therefor
DE60231057D1 (de) * 2001-12-17 2009-03-19 Serono Lab Chemokine mutanten, die als chemokine antagonisten wirken
US20040191215A1 (en) * 2003-03-25 2004-09-30 Michael Froix Compositions for induction of a therapeutic response
US7390788B2 (en) * 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
WO2008015199A1 (en) * 2006-07-31 2008-02-07 Laboratoires Serono S.A. Chemokine antagonists
DK2185719T3 (en) 2007-08-02 2014-02-17 Novimmune Sa ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
AU2011213559B2 (en) 2010-02-08 2015-05-07 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
AU2022359841A1 (en) 2021-10-06 2024-05-02 Virothera Ltd Novel immune regulator

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0796330A1 (en) * 1994-12-08 1997-09-24 Glaxo Group Limited Rantes peptide and fragments and compositions comprising it for treatment of inflammation

Also Published As

Publication number Publication date
CZ171997A3 (en) 1997-11-12
AU4120896A (en) 1996-06-26
EP0796330A1 (en) 1997-09-24
CN1168697A (zh) 1997-12-24
CA2207036A1 (en) 1996-06-13
US6555105B1 (en) 2003-04-29
WO1996017935A3 (en) 1996-08-22
NZ296570A (en) 1998-11-25
CZ290850B6 (cs) 2002-10-16
PL182786B1 (pl) 2002-02-28
NO972620D0 (no) 1997-06-06
PL320565A1 (en) 1997-10-13
US6159711A (en) 2000-12-12
BR9509890A (pt) 1997-12-30
JPH10510151A (ja) 1998-10-06
FI972433A (fi) 1997-06-06
HU221089B1 (en) 2002-08-28
WO1996017935A2 (en) 1996-06-13
NO972620L (no) 1997-08-06
FI972433A0 (fi) 1997-06-06
HUT77075A (hu) 1998-03-02
CN1087346C (zh) 2002-07-10
AU688641B2 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
MX9703889A (es) Peptido rantes y fragmentos y composiciones que lo contienen, para el tratamiento de la inflamacion.
PL312481A1 (en) Application of cgrp antagonist in cosmetic, pharmaceutical or dermatological composition and so obtained composition as such
AP9600794A0 (en) Pharmaceutical compositions containing novel compounds and their use in treating allergic and inflammatory diseases
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
IL122733A0 (en) Pharmaceutical compositions for use in the treatment of allergic asthma
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
ATE221125T1 (de) Klonierte glutaminsäure-decarboxylase
MY106272A (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants.
HK1003709A1 (en) Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
BG102362A (en) New derivatives of amino acids, their preparation and application
GB8805792D0 (en) Medicaments
ITRM940328A0 (it) "uso di prodotti contenenti magnesio nella terapia e nella profilassi di malattie neoplastiche e di malattie di tipo autoimmunitario".-
AU9084191A (en) Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke
ZA943171B (en) Thrombin-inhibitors.
ES2005522A4 (es) Peptidos con grupos ester sulfato.
GB9519737D0 (en) Polypeptides and their use in treatment and prophylaxis of auto-immune
HU9600934D0 (en) Oligopeptides derived from c-reactive protein fragments
MX9606674A (es) Tratamiento de enfermedades humanas que involucran la desregulacion o disfuncion del sistema nervioso.
IL91451A0 (en) Pharmaceutical compositions comprising azapiron compounds and their use in the treatment of addiction
BG101849A (en) Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions
AU3752189A (en) Pharmaceutical compositions and use thereof in treating inflammation
IT1251497B (it) Uso di 1,2 dipalmitoil-l-alfa-fosfatidil-n,n-dimetiletanolammina, in composizioni dermatologiche
BG101325A (en) Use of muramyl peptide compounds
NZ310366A (en) Haemopoietic growth factor antagonists and uses therefor
DE59207735D1 (de) Neues thrombininhibitorisches protein aus zecken